Giovanni Luca Ceresoli

Giovanni Luca Ceresoli is an expert in Oncology at Humanitas Gavazzeni (Italy). As of September 2026, ScienceLeadR ranks Giovanni Luca Ceresoli in the top 1% of experts worldwide for Mesothelioma, Adenoma and Thoracic Neoplasms. Giovanni Luca Ceresoli has authored 301 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 2 of them ongoing. SLR score: 1,178 (community average: 125). How the SLR is computed.

Oncology

Subspecialties: Radiotherapy - Pulmonology - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on September 4, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2026

Source: PubMed

Humanitas Gavazzeni

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 301

Citations

Citations: 10 171 1st author: 60 Last author: 24 Unique author: 3

Main journals

Int J Radiat Oncol Biol Phys 11

Best Journals

J Clin Oncol 7

Lancet Oncol 7

Ann Oncol 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year
Brief report: attitudes and barriers toward genetic testing in pleural mesothelioma: a nationwide Italian survey. PMID 42496771 — research design, genetic testing, mesothelioma, physicians	Fam Cancer	2026
CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma. PMID 42308637 — pemetrexed, mesothelioma, chimera, drug therapy, immunotherapy, lung neoplasms, therapeutics, carboplatin, chemotherapy	Clin Lung Cancer	2026
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study. PMID 41747469 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, diagnosis, therapeutics	Cancer Treat Res Commun	2026
Pericardial Mesothelioma: Diagnostic and Therapeutic Management, a Population-Based Study in Italy. PMID 41375067 — mesothelioma, work, therapeutics, prognosis	Cancers (Basel)	2025
Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions. PMID 41097726 — thoracic neoplasms, mesothelioma, neoplasms, drug therapy, immunotherapy, therapeutics, chemotherapy	Cancers (Basel)	2025

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 2 6

Phase 2/Phase 3 4

N/A 3

Phase 3 2

By status:

Completed 11

Active not recruiting 1

Recruiting 1

Terminated 1

Unknown 1

By type:

Interventional 12

Observational 3

By Monocentric/Multicentric:

monocentric 5

multicentric2to4 0

multicentric5to9 1

multicentricup10 9

Main Topics

Respiratory Tract Diseases 14

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs Investigator s Choice of the Standard of Care in Unresectable Pleural Mesothelioma 2023-503231-17-00 — pemetrexed, mesothelioma, nivolumab, therapeutics, ipilimumab, carboplatin	Phase 3	Active not recruiting	2024
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study NCT05538806 — mesothelioma, mesothelioma, malignant	N/A	Recruiting	2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice